عوامل مضادة لمستقبل تاكيكينين tachykininمشتقة من مورفولين morpholineوثيومورفولين thiomorpholine

الملخص: يتعلق الإختراع الحالى بدوائر مغايرة مستبدلة substituted heterocycles من الصيغة البنائية العامة: Substituted heterocycles of general structural formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is selected from the group consisting of: hydrogen; C1-6 alkyl, unsubstituted o...

Full description

Saved in:
Bibliographic Details
Main Authors SHAH, SHREINK K, HARRISON, TIMOTHY, LADDUWAHETTY, TAMARA, WILLIAMS, BRIAN G, FINKE, PAUL E, MACCOSS, MALCOM, DORN, CONRAD P, CHAMBERS, MARL S, MILLS, SANDER G, HALE, JEFFREY J
Format Patent
LanguageArabic
Published 15.03.2006
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:الملخص: يتعلق الإختراع الحالى بدوائر مغايرة مستبدلة substituted heterocycles من الصيغة البنائية العامة: Substituted heterocycles of general structural formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is selected from the group consisting of: hydrogen; C1-6 alkyl, unsubstituted or substituted; C2-6 alkenyl, unsubstituted or substituted; C2-6 alkynyl; phenyl, unsubstitued or substituted; X is selected from the group consisting of: -O-, -S-, -SO-, -SO2-; Y is selected from the group consisting of: a single bond, -O-, -S-, -CO-, -CH2, -CHR5- and -CR R ; Z = C1-6 alkyl, are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
Bibliography:Application Number: SA19950150523